» Articles » PMID: 16293724

Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-axin-beta-catenin Signaling Axis

Overview
Journal Science
Specialty Science
Date 2005 Nov 19
PMID 16293724
Citations 408
Authors
Affiliations
Soon will be listed here.
Abstract

How cyclooxygenase-2 (COX-2) and its proinflammatory metabolite prostaglandin E2 (PGE2) enhance colon cancer progression remains poorly understood. We show that PGE2 stimulates colon cancer cell growth through its heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptor, EP2, by a signaling route that involves the activation of phosphoinositide 3-kinase and the protein kinase Akt by free G protein betagamma subunits and the direct association of the G protein alphas subunit with the regulator of G protein signaling (RGS) domain of axin. This leads to the inactivation and release of glycogen synthase kinase 3beta from its complex with axin, thereby relieving the inhibitory phosphorylation of beta-catenin and activating its signaling pathway. These findings may provide a molecular framework for the future evaluation of chemopreventive strategies for colorectal cancer.

Citing Articles

Missense Mutant p53 Transactivates Wnt/β-Catenin Signaling in Neighboring p53-Destabilized Cells through the COX-2/PGE2 Pathway.

Nakayama M, Saito H, Murakami K, Oshima H, Oshima M Cancer Res Commun. 2024; 5(1):13-23.

PMID: 39641656 PMC: 11695814. DOI: 10.1158/2767-9764.CRC-24-0471.


PTGER4 signaling regulates class IIa HDAC function and SPINK4 mRNA levels in rectal epithelial cells.

Anbazhagan M, Sharma G, Murthy S, Maddipatla S, Kolachala V, Dodd A Cell Commun Signal. 2024; 22(1):493.

PMID: 39396982 PMC: 11472582. DOI: 10.1186/s12964-024-01879-1.


Determination of the frequency and distribution of APC, PIK3CA, and SMAD4 gene mutations in Ugandan patients with colorectal cancer.

Wismayer R, Matthews R, Whalley C, Kiwanuka J, Kakembo F, Thorn S BMC Cancer. 2024; 24(1):1212.

PMID: 39350061 PMC: 11440721. DOI: 10.1186/s12885-024-12967-3.


Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated G in Human Cancer.

Dwyer M, Aumiller J, Wedegaertner P Mol Pharmacol. 2024; 106(5):198-215.

PMID: 39187387 PMC: 11493338. DOI: 10.1124/molpharm.124.000743.


New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies.

Nag J, Appasamy P, Malka H, Sedley S, Bar-Shavit R Int J Mol Sci. 2024; 25(15).

PMID: 39125653 PMC: 11311281. DOI: 10.3390/ijms25158083.